Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
31.41
-0.62 (-1.94%)
Nov 25, 2025, 4:00 PM EST - Market closed
Viridian Therapeutics Employees
Viridian Therapeutics had 143 employees as of December 31, 2024. The number of employees increased by 49 or 52.13% compared to the previous year.
Employees
143
Change (1Y)
49
Growth (1Y)
52.13%
Revenue / Employee
$495,028
Profits / Employee
-$1,715,510
Market Cap
3.00B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 143 | 49 | 52.13% |
| Dec 31, 2023 | 94 | 8 | 9.30% |
| Dec 31, 2022 | 86 | 36 | 72.00% |
| Dec 31, 2021 | 50 | 23 | 85.19% |
| Dec 31, 2020 | 27 | -19 | -41.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VRDN News
- 18 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 19 days ago - Viridian Therapeutics Is Ready For An Eventful 2026 - Seeking Alpha
- 20 days ago - Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire
- 22 days ago - Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease - Business Wire
- 5 weeks ago - Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock - Business Wire
- 5 weeks ago - Viridian Therapeutics Announces Proposed Underwritten Public Offering - Business Wire
- 5 weeks ago - Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million - Business Wire
- 2 months ago - Viridian Therapeutics: De-Risked Leadership In Thyroid Eye Disease - Seeking Alpha